medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-11-14-19medsovet-1140Research ArticleХОБЛВыбор оптимального антибактериального препарата для терапии обострений хронической обструктивной болезни легкихSelecting adequate antibacterial therapy for the treatment of COPD exacerbationsЛазареваН. Б.LazarevN. B.noemail@neicon.ruГБОУ ВПО «Первый Московский медицинский университет им. И.М. Сеченова»РоссияFirst Moscow Medical University named after I.M. SechenovRussian Federation2013301220130111419Copyright © Лазарева Н.Б., 20132013Лазарева Н.Б.Lazarev N.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1140

Обострения ХОБЛ негативно влияют на качество жизни пациента, ухудшают клинические симптомы и функцию легких, служат основной причиной обращений за медицинской помощью, ассоциируются со значительной летальностью и, как следствие, приводят к значительным социально-экономическим издержкам. Принимая во внимание современные рекомендации по лечению ХОБЛ и данные исследований по резистентности респираторных патогенов, защищенные пенициллины для перорального приема могут быть отнесены к препаратам первого выбора при проведении эмпирической антибактериальной терапии при обострениях ХОБЛ легкой и средней степени тяжести.

COPD exacerbations have a negative impact on patient's quality of life, lead to worsening of clinical symptoms and function of the lung. COPD, being a major cause of seeking medical aid, is associated with a significant mortality and results in considerable economic and social costs. Taking into account current recommendations for the treatment of COPD and research data on the resistance of respiratory pathogens, inhibitor-protected penicillin for oral administration may be considered a medicine of choice in the empirical antibiotic therapy for mild to moderate COPD exacerbations.

хроническая обструктивная болезнь легкихантибактериальная терапиязащищенные пенициллиныchronic obstructive pulmonary diseaseantibiotic therapyinhibitor-protected penicillinsReferencesMiravitlles M., Torres A. Antibiotics in exacerbations of COPD: lessons from the past // Eur. Respir. J. 2004. №24. P. 896–897.Miravitlles M., Torres A. Antibiotics in exacerbations of COPD: lessons from the past // Eur. Respir. J. 2004. №24. P. 896–897.Wilson R. Bacteria, antibiotics and COPD // Eur. Respir. J. 2001. №17. P. 995–1007.Wilson R. Bacteria, antibiotics and COPD // Eur. Respir. J. 2001. №17. P. 995–1007.Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease // N. Engl. J. Med. 2008. №359. P. 2355–65.Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease // N. Engl. J. Med. 2008. №359. P. 2355–65.Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection // Eur. Respir. J. 1995. №8. P. 1333–1338.Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection // Eur. Respir. J. 1995. №8. P. 1333–1338.Anthonison N.R. The British hypothesis revisited // Eur. Respir. J. 2004. №23. P. 657–658.Anthonison N.R. The British hypothesis revisited // Eur. Respir. J. 2004. №23. P. 657–658.Sethi S., Evans N., Grant B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease //N. Engl. J. Med. 2002. №347. P. 465–471.Sethi S., Evans N., Grant B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease //N. Engl. J. Med. 2002. №347. P. 465–471.Stockley R.A., O’Brien C., Pye A. et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD // Chest. 2001. №117. P. 1638–1645.Stockley R.A., O’Brien C., Pye A. et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD // Chest. 2001. №117. P. 1638–1645.Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J., Murphy T.F. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care. Med. 2007 Aug 15. №176(4). P. 356–61. Epub. 2007. May 3.Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J., Murphy T.F. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease // Am. J. Respir. Crit. Care. Med. 2007 Aug 15. №176(4). P. 356–61. Epub. 2007. May 3.Bandi V., Jakubowycz M., Kinyon C. et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae // FEMS Immunol. Med. Microbiol. 2003. №37. P. 69–75.Bandi V., Jakubowycz M., Kinyon C. et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae // FEMS Immunol. Med. Microbiol. 2003. №37. P. 69–75.Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents // J. Antimicrob. Chemother. №52. P. 229– 246.Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents // J. Antimicrob. Chemother. №52. P. 229– 246.Johnson D.M., Biedenbach D.J., Beach M.L., Pfaller M.A., Jones R.N. Antimicrobial activity and in vitro susceptibility testdevelopment for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species // Diagn. Microbiol. Infect. Dis. №37. P. 99–105.Johnson D.M., Biedenbach D.J., Beach M.L., Pfaller M.A., Jones R.N. Antimicrobial activity and in vitro susceptibility testdevelopment for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species // Diagn. Microbiol. Infect. Dis. №37. P. 99–105.Sader H.S., Fritsche T.R., Mutnick A.H., Jones R.N. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000–2002) // Diagn. Microbiol. Infect. Dis. №47. P. 515–525.Sader H.S., Fritsche T.R., Mutnick A.H., Jones R.N. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000–2002) // Diagn. Microbiol. Infect. Dis. №47. P. 515–525.Ram F.S., Rodriguez-Roisin R., Barnes N.С. Antibiotics for exacerbations of chronic obstructive pulmonary disease // Cochrane Database Syst. Rev. January 1. 2006. №(2). CD004403.Ram F.S., Rodriguez-Roisin R., Barnes N.С. Antibiotics for exacerbations of chronic obstructive pulmonary disease // Cochrane Database Syst. Rev. January 1. 2006. №(2). CD004403.Quon B.S., Gan W.Q., Sin D.D. Contemporary management of acute exacerbations of COPD: a systemic review and meta-analysis // Chest. 2008. №133. P. 756–66.Quon B.S., Gan W.Q., Sin D.D. Contemporary management of acute exacerbations of COPD: a systemic review and meta-analysis // Chest. 2008. №133. P. 756–66.Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/.Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/.Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections // Eur. Respir. J. 2005. №26. P. 1138–1380.Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections // Eur. Respir. J. 2005. №26. P. 1138–1380.Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD // Chest 1999. №116(1). P. 40–46.Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD // Chest 1999. №116(1). P. 40–46.Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position-paper // Eur. Respir. J. 2004. №23(6). P. 932–946.Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position-paper // Eur. Respir. J. 2004. №23(6). P. 932–946.Anzeuto A., Bishai W.R., Pottumarthy S. Role of oral extendedspectrum cephems in the treatment of acute exacerbation of chronic bronchitis: focus on cefdinir. P. 39–44.Anzeuto A., Bishai W.R., Pottumarthy S. Role of oral extendedspectrum cephems in the treatment of acute exacerbation of chronic bronchitis: focus on cefdinir. P. 39–44.

The authors declare that there are no conflicts of interest present.